I previously outlined annual $ spend for all top rx, and it’s a big sum. To answer your question =. Generics don’t spend or build a new market. Not their mo.
They would much rather feed off a developed market. That’s why if no settlement and Amrn loses appeal then generics are stuck w a drug they can’t/won’t cultivate the market.
That is key why generics have motivation to settle. Amrn knows this. And it gives Amrn leverage to negotiate a settlement
News 
Market Data 
Discover 
